Frovatriptan | CAS#158747-02-5 | ligand

MedKoo Cat#: 584736 | Name: Frovatriptan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Frovatriptan is a high-affinity 5-HT(1B/1D)-receptor ligand shown to be effective against migraines.

Chemical Structure

Frovatriptan

CAS#158747-02-5 (free base)

Theoretical Analysis

MedKoo Cat#: 584736

Name: Frovatriptan

CAS#: 158747-02-5 (free base)

Chemical Formula: C14H17N3O

Exact Mass: 243.1372

Molecular Weight: 243.31

Elemental Analysis: C, 69.11; H, 7.04; N, 17.27; O, 6.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

158747-02-5 (free base) 158930-09-7 (succinate) Frovatriptan succinate hydrate

Synonym

Frovatriptan; Miguard; Frova; Allergo filmtabletten; SB 209509; SB209509; SB-209509;

IUPAC/Chemical Name

1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3R)-

InChi Key

XPSQPHWEGNHMSK-SECBINFHSA-N

InChi Code

InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1

SMILES Code

O=C(C1=CC2=C(NC3=C2C[C@H](NC)CC3)C=C1)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 243.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Allais G, Benedetto C. Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. Drug Des Devel Ther. 2016 Oct 3;10:3225-3236. eCollection 2016. Review. PubMed PMID: 27757013; PubMed Central PMCID: PMC5055118. 2: Saracheva KE, Prissadova NA, Turiiski VI, Slavchev VI, Krastev AD, Getova DP. Effects of the Novel High-affinity 5-HT(1B/1D)-receptor Ligand Frovatriptan on the Rat Carotid Artery. Folia Med (Plovdiv). 2017 Mar 1;59(1):31-36. doi: 10.1515/folmed-2017-0006. PubMed PMID: 28384110. 3: Seo JG, Park SP. Factors associated with frovatriptan response in patients with migraine: A prospective, observational study. Cephalalgia. 2016 Apr;36(5):493-8. doi: 10.1177/0333102415596443. Epub 2015 Jul 13. PubMed PMID: 26170008. 4: Cady RK, Farmer K. Managing migraine by patient profile: role of frovatriptan. Patient Prefer Adherence. 2016 Apr 5;10:501-10. doi: 10.2147/PPA.S85795. eCollection 2016. Review. PubMed PMID: 27103792; PubMed Central PMCID: PMC4829192. 5: Allais G, Bussone G, Tullo V, Cortelli P, Valguarnera F, Barbanti P, Sette G, D'Onofrio F, Curone M, Benedetto C. Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial. Cephalalgia. 2015 Jan;35(1):45-50. doi: 10.1177/0333102414542290. Epub 2014 Jul 22. PubMed PMID: 25053749; PubMed Central PMCID: PMC4261077. 6: MacGregor EA. A review of frovatriptan for the treatment of menstrual migraine. Int J Womens Health. 2014 May 21;6:523-35. doi: 10.2147/IJWH.S63444. eCollection 2014. Review. PubMed PMID: 24904224; PubMed Central PMCID: PMC4039425. 7: Evers S, Savi L, Omboni S, Lisotto C, Zanchin G, Pinessi L. Efficacy of frovatriptan as compared to other triptans in migraine with aura. J Headache Pain. 2015;16:514. doi: 10.1186/s10194-015-0514-8. Epub 2015 Apr 1. PubMed PMID: 25916333; PubMed Central PMCID: PMC4397219. 8: Allais G, Bussone G, Tullo V, Cortelli P, Valguarnera F, Barbanti P, Sette G, Frediani F, D'Arrigo G, d'Onofrio F, Comi G, Curone M, Colombo B, Omboni S, Benedetto C. Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group study. Neurol Sci. 2015 May;36 Suppl 1:161-7. doi: 10.1007/s10072-015-2165-6. Erratum in: Neurol Sci. 2016 Feb;37(2):331. PubMed PMID: 26017535. 9: Rudingwa P, Pannerselvam S. Implications of Pediatric Frova length in airway management. Paediatr Anaesth. 2017 Sep;27(9):975-976. doi: 10.1111/pan.13197. PubMed PMID: 28772012. 10: Saracco MG, Allais G, Tullo V, Zava D, Pezzola D, Reggiardo G, Omboni S, Benedetto C, Bussone G, Aguggia M. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies. Neurol Sci. 2014 May;35 Suppl 1:115-9. doi: 10.1007/s10072-014-1752-2. Review. PubMed PMID: 24867847. 11: Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs. 2012 Sep 1;26(9):791-811. doi: 10.2165/11209380-000000000-00000. Review. PubMed PMID: 22900951. 12: Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017 Feb;57(2):194-208. doi: 10.1111/head.12978. Epub 2016 Dec 2. Review. PubMed PMID: 27910087. 13: Lisotto C, Guidotti M, Zava D, Savi L. Frovatriptan and rizatriptan economic EVAluation: the FREEVA study. J Headache Pain. 2013 Dec 11;14:96. doi: 10.1186/1129-2377-14-96. PubMed PMID: 24330707; PubMed Central PMCID: PMC3878870. 14: Savi L, Mogavero S, Egan CG. Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. Drug Des Devel Ther. 2014 Jul 21;8:983-92. doi: 10.2147/DDDT.S61295. eCollection 2014. PubMed PMID: 25092964; PubMed Central PMCID: PMC4112748. 15: Allais G, Tullo V, Cortelli P, Barbanti P, Valguarnera F, Sette G, D'Onofrio F, Curone M, Zava D, Pezzola D, Reggiardo G, Omboni S, Frediani F, Bussone G, Benedetto C. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura. Neurol Sci. 2014 May;35 Suppl 1:107-13. doi: 10.1007/s10072-014-1751-3. PubMed PMID: 24867846; PubMed Central PMCID: PMC4035546. 16: Macone AE, Perloff MD. Triptans and migraine: advances in use, administration, formulation, and development. Expert Opin Pharmacother. 2017 Mar;18(4):387-397. doi: 10.1080/14656566.2017.1288721. Epub 2017 Feb 14. Review. PubMed PMID: 28129702. 17: Tullo V, Valguarnera F, Barbanti P, Cortelli P, Sette G, Allais G, d'Onofrio F, Curone M, Zava D, Pezzola D, Benedetto C, Frediani F, Bussone G. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia. 2014 May;34(6):434-45. doi: 10.1177/0333102413515342. Epub 2013 Dec 20. Erratum in: Cephalalgia. 2015 Mar;35(3):286. Cephalalgia. 2015 Mar;35(3):286. PubMed PMID: 24363238. 18: Møller-Helgestad OK, Kaltoft AK, Kasch H. [Frovatriptan possibly causing acute myocardial infarction]. Ugeskr Laeger. 2015 Mar 23;177(13):V10140537. Danish. PubMed PMID: 25822816. 19: Beleña JM, Gasco C, Polo CE, Vidal A, Núñez M, Lopez-Timoneda F. Laryngeal mask, laryngeal tube, and Frova introducer in simulated difficult airway. J Emerg Med. 2015 Feb;48(2):254-9. doi: 10.1016/j.jemermed.2014.09.038. Epub 2014 Nov 6. PubMed PMID: 25453860. 20: Tullo V, Bussone G, Omboni S, Barbanti P, Cortelli P, Curone M, Peccarisi C, Benedetto C, Pezzola D, Zava D, Allais G. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies. Neurol Sci. 2013 May;34 Suppl 1:S87-91. doi: 10.1007/s10072-013-1367-z. Review. PubMed PMID: 23695053.